Literature DB >> 19773542

Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.

David E Moody1, Wenfang B Fang, Shen-Nan Lin, Denise M Weyant, Stephen C Strom, Curtis J Omiecinski.   

Abstract

We tested the hypothesis that primary cultures of human hepatocytes could predict potential drug interactions with methadone and buprenorphine. Hepatocytes (five donors) were preincubated with dimethyl sulfoxide (DMSO) (vehicle), rifampin, or nelfinavir before incubation with methadone or buprenorphine. Culture media (0-60 min) was analyzed by liquid chromatography-tandem mass spectrometry for R- and S-methadone and R- and S-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) or for buprenorphine, norbuprenorphine, and their glucuronides [buprenorphine-3-glucuronide (B-3-G) and norbuprenorphine-3-glucuronide (N-3-G)]. R- and S-EDDP were detected in three of five, four of five, and five of five media from cells pretreated with DMSO, nelfinavir, and rifampin. R-EDDP increased 3.1- and 26.5-fold, and S-EDDP increased 2.5- and 21.3-fold after nelfinavir and rifampin. The rifampin effect was significant. B-3-G production was detected in media of all cells incubated with buprenorphine and accounted for most of the buprenorphine loss from culture media; it was not significantly affected by either pretreatment. Norbuprenorphine and N-3-G together were detected in three of five, four of five, and five of five donors pretreated with DMSO, nelfinavir and rifampin, and norbuprenorphine in one of five, one of five, and two of five donors. Although there was a trend for norbuprenorphine (2.8- and 4.9-fold) and N-3-G (1.7- and 1.9-fold) to increase after nelfinavir and rifampin, none of the changes were significant. To investigate low norbuprenorphine production, buprenorphine was incubated with human liver and small intestine microsomes fortified to support both N-dealkylation and glucuronidation; N-dealkylation predominated in small intestine and glucuronidation in liver microsomes. These studies support the hypothesis that methadone metabolism and its potential for drug interactions can be predicted with cultured human hepatocytes, but for buprenorphine the combined effects of hepatic and small intestinal metabolism are probably involved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773542      PMCID: PMC2784702          DOI: 10.1124/dmd.109.028605

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  37 in total

1.  The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry.

Authors:  Wei Huang; David E Moody; Elinore F McCance-Katz
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

2.  ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.

Authors:  Séverine Crettol; Jean-Jacques Déglon; Jacques Besson; Marina Croquette-Krokar; Robert Hämmig; Isabelle Gothuey; Martine Monnat; Chin B Eap
Journal:  Clin Pharmacol Ther       Date:  2006-12       Impact factor: 6.875

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes.

Authors:  C Iribarne; D Picart; Y Dréano; J P Bail; F Berthou
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

5.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

6.  In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.

Authors:  Nicolas Picard; Thierry Cresteil; Nassim Djebli; Pierre Marquet
Journal:  Drug Metab Dispos       Date:  2005-03-02       Impact factor: 3.922

7.  P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide.

Authors:  Keith A Hoffmaster; Ryan Z Turncliff; Edward L LeCluyse; Richard B Kim; Peter J Meier; Kim L R Brouwer
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

8.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

9.  Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington; Alysa Walker; Pamela Sheffels Bedynek
Journal:  Anesthesiology       Date:  2009-03       Impact factor: 7.892

10.  A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies.

Authors:  David E Moody; Matthew H Slawson; Eric C Strain; John D Laycock; Alan C Spanbauer; Rodger L Foltz
Journal:  Anal Biochem       Date:  2002-07-01       Impact factor: 3.365

View more
  5 in total

1.  Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Authors:  David E Moody; Wenfang B Fang; Jerdravee Morrison; Elinore McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

Review 2.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

3.  Sex specific effects of buprenorphine on behavior, astrocytic opioid receptor expression and neuroinflammation after pediatric traumatic brain injury in mice.

Authors:  Yesmine Hamood; Mauda Abdullah; Hassan El Ghoul; Nazeh Saad; Robert C Dysko; Zhi Zhang
Journal:  Brain Behav Immun Health       Date:  2022-05-13

4.  Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.

Authors:  Hsin-Ya Lee; Jih-Heng Li; Li-Tzy Wu; Jin-Song Wu; Cheng-Fang Yen; Hsin-Pei Tang
Journal:  Subst Abuse Treat Prev Policy       Date:  2012-03-20

5.  Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters.

Authors:  Kelly Bleasby; Robert Houle; Michael Hafey; Meihong Lin; Jingjing Guo; Bing Lu; Rosa I Sanchez; Kerry L Fillgrove
Journal:  Viruses       Date:  2021-08-07       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.